Showing results 1 to 20 of 20
|A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma
|Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments
|BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis
|노진, 정성현, 최윤석
|Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
|Clinical significance of post-treatment (18)F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma
|안영실, 윤준기, 이수진, 이현우, 정성현
|Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells.
|Cutaneous Lymphoma in Korea: A Nationwide Retrospective Study
|High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy
|강석윤, 김장희, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁, 한재호
|Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
|Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
|Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
|강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁
|Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
|Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.
|Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions.
|Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
|Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
|Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma
|강대용, 안영실, 윤준기, 이수진, 이현우, 정성현
|Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
|노진, 박준성, 정성현, 한재호
|Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?
|Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined with Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma
|노진, 박준성, 정성현, 최윤석